Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Division of Hematology/Oncology

Northwestern University

676 North St. Clair Street

Suite 850

USA

Name/email consistency: high

Division of Hematology/Oncology, Northwestern University, 676 North St. Clair Street, Suite 850, USA. 2006 - 2011
Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, USA. 2004
Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, USA. 2003

Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Kaklamani, V.G., Siziopikou, K., Scholtens, D., Lacouture, M., Gordon, J., Uthe, R., Meservey, C., Hansen, N., Khan, S.A., Jeruss, J.S., Bethke, K., Cianfrocca, M., Rosen, S., Von Roenn, J., Wayne, J., Parimi, V., Jovanovic, B., Gradishar, W. Breast Cancer Res. Treat. (2011) [Pubmed]
Global experience with ixabepilone in breast cancer. Kaklamani, V.G., Xu, B.H., Gomez, H.L. Expert. Rev. Anticancer. Ther (2011) [Pubmed]
A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Kaklamani, V. Expert Rev. Mol. Diagn. (2006) [Pubmed]
Role of TGF-beta in cancer and the potential for therapy and prevention. Kaklamani, V.G., Pasche, B. Expert. Rev. Anticancer. Ther (2004) [Pubmed]
Role of capecitabine (Xeloda) in breast cancer. Kaklamani, V.G., Gradishar, W.J. Expert. Rev. Anticancer. Ther (2003) [Pubmed]